CompletedPhase 1

Impact of Metformin on Immunity

United States18 participantsStarted 2019-01-14

Plain-language summary

To determine whether metformin (MET) can improve the immune response to the pneumococcal conjugate vaccine (PCV-13) in older adults.

Age range63 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Previous vaccination with any pneumococcal vaccine
✕. Metformin within the last 6 months
✕. Contraindication for PCV13
✕. History of severe adverse reaction associated with any vaccine component
✕. Residence in long-term care facility
✕. Diagnosis of diabetes (diagnosis of pre-diabetes okay)
✕. Chronic renal disease (or eGFR \<50 mL/min) or renal failure (defined as receipt of renal dialysis or transplant) or nephrotic syndrome
✕. History of adverse reaction or contraindications associated with metformin

Change in antibody responses to PCV13

Timeframe: Change from 4 weeks to 8 weeks

NCT IDNCT03713801

SponsorThe University of Texas Health Science Center at San Antonio

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-16